We demonstrated here that treatment of an anti-mouse IL-6 receptor antibody (MR16-1) suppressed atherosclerosis lesion in atherogenic mice via the inhibition of IL-6–STAT3 signaling pathway. This evidence concerns the gene IL6 and atherosclerosis.